U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.
Status:
US Animal Drug
Source:
GREEN BOOK:EPINEPHRINE ACETATE [GREEN BOOK]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Animal Drug
Source:
GREEN BOOK:FLUMETHASONE ACETATE [GREEN BOOK]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Conditions:

Flumethasone 21-acetate is an anti-inflammatory corticosteroid. It has 300 times greater anti-inflammatory activity and 677 times greater capacity to promote liver glycogen deposition than hydrocortisone. It has anti-rheumatic potency 31 times higher than cortisol.
Status:
Investigational
Source:
NCT01549015: Not Applicable Interventional Completed Urea Cycle Disorders
(2012)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
USAN:GILDEURETINOL ACETATE [USAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Alkeus Pharma's lead compound, ALK-001, is an oral compound with a well-understood mechanism of action. ALK-001 was specifically designed to prevent the formation of these toxic vitamin A dimers in the eye. ALK-001 is a chemically-modified vitamin A, in which 3 hydrogen atoms have been replaced by 3 deuterium atoms at carbon number 20. Replacing the retina's vitamin A with ALK-001 slows the formation of toxic vitamin A dimers. ALK-001 is in phase II clinical trials for the treatment of Stargardt's disease. The compound was co-developed by Alkeus Pharmaceuticals and Columbia University.
Status:
Investigational
Source:
USAN:MERISOPROL ACETATE HG 203 [USAN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
USAN:MERISOPROL ACETATE HG 197 [USAN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
NCT03016221: Not Applicable Interventional Completed Healthy
(2017)
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Status:
Investigational
Source:
NCT00302731: Phase 2 Interventional Terminated Menopause
(2006)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT02415439: Phase 1 Interventional Completed Healthy
(2015)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)